Ipca Labs Q2 profit rises 32.5% to ₹375 crore
In short
IPCA Laboratories said its Q2 net profit rose 32.5% to ₹375 crore, while revenue grew 13.8% to ₹2,910 crore. EBITDA margin improved to 23%.
The results matter because stronger margins support earnings, even though Unichem booked a ₹24.26-crore provision tied to a UK legal claim.
What the reporting says
IPCA Laboratories reported a 32.5% year-on-year rise in Q2 net profit to ₹375 crore, while revenue increased 13.8% to ₹2,910 crore. CNBC TV18 Market said EBITDA margin improved to 23%, even as subsidiary Unichem recognised a ₹24.26-crore provision linked to a UK legal claim. The results point to stronger operating performance, partly offset by the legal provision.
Why it matters
IPCA Laboratories reported stronger Q2 earnings, with net profit up 32.5% to ₹375 crore and revenue up 13.8% to ₹2,910 crore. EBITDA margin improved to 23%, showing better operating performance. The quarter also included a ₹24.26-crore provision at subsidiary Unichem tied to a UK legal claim, which weighed on the overall picture.